JP2013537905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537905A5 JP2013537905A5 JP2013530121A JP2013530121A JP2013537905A5 JP 2013537905 A5 JP2013537905 A5 JP 2013537905A5 JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013537905 A5 JP2013537905 A5 JP 2013537905A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- interleukin
- additional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 0 C*C(N[C@@](C1CCOCC1)C(N([C@]1[C@](C2)[C@]1C)[C@@]2c1cnc(-c(cc2)ccc2C#Cc(cc2)ccc2-c2ncc([C@](C[C@@]3[C@@]4[C@]3C)N4C([C@](C3CCOCC3)NC(O)=O)=O)[n]2)[n]1)=O)=O Chemical compound C*C(N[C@@](C1CCOCC1)C(N([C@]1[C@](C2)[C@]1C)[C@@]2c1cnc(-c(cc2)ccc2C#Cc(cc2)ccc2-c2ncc([C@](C[C@@]3[C@@]4[C@]3C)N4C([C@](C3CCOCC3)NC(O)=O)=O)[n]2)[n]1)=O)=O 0.000 description 2
- MNKIODQOJLMNMB-LKOLDZRLSA-N C[C@H]([C@@H]1C2)[C@H]1N[C@@H]2c1cnc(-c(cc2)ccc2C#Cc(cc2)ccc2-c2ncc([C@H]3N[C@@H](C4)[C@]4(C)C3)[nH]2)[nH]1 Chemical compound C[C@H]([C@@H]1C2)[C@H]1N[C@@H]2c1cnc(-c(cc2)ccc2C#Cc(cc2)ccc2-c2ncc([C@H]3N[C@@H](C4)[C@]4(C)C3)[nH]2)[nH]1 MNKIODQOJLMNMB-LKOLDZRLSA-N 0.000 description 1
- HCDZFGVDKDJPSH-ZTRUCFIOSA-N C[C@H]([C@@H]1C[C@H]2c3cnc(-c(cc4)ccc4C#Cc(cc4)ccc4-c4ncc([C@H]5N[C@@H](C6)[C@@]6(C)C5)[nH]4)[nH]3)[C@H]1N2C(OC(C)(C)C)=O Chemical compound C[C@H]([C@@H]1C[C@H]2c3cnc(-c(cc4)ccc4C#Cc(cc4)ccc4-c4ncc([C@H]5N[C@@H](C6)[C@@]6(C)C5)[nH]4)[nH]3)[C@H]1N2C(OC(C)(C)C)=O HCDZFGVDKDJPSH-ZTRUCFIOSA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/050138 WO2012039717A1 (en) | 2010-09-24 | 2010-09-24 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537905A JP2013537905A (ja) | 2013-10-07 |
| JP2013537905A5 true JP2013537905A5 (enExample) | 2013-11-14 |
| JP5619289B2 JP5619289B2 (ja) | 2014-11-05 |
Family
ID=43037168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530121A Expired - Fee Related JP5619289B2 (ja) | 2010-09-24 | 2010-09-24 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2619195A1 (enExample) |
| JP (1) | JP5619289B2 (enExample) |
| CN (1) | CN103249730A (enExample) |
| BR (1) | BR112013008148A2 (enExample) |
| CA (1) | CA2812699A1 (enExample) |
| EA (1) | EA201370078A1 (enExample) |
| MX (1) | MX2013002927A (enExample) |
| WO (1) | WO2012039717A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| PL2628481T3 (pl) | 2009-06-11 | 2016-08-31 | Abbvie Bahamas Ltd | Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012027712A2 (en) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| WO2013118097A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| CA2873341C (en) | 2012-06-04 | 2018-01-02 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| MX366642B (es) | 2013-12-04 | 2019-07-17 | Idorsia Pharmaceuticals Ltd | Uso de derivados de bencimidazol-prolina. |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN113979962A (zh) | 2017-03-31 | 2022-01-28 | 先正达参股股份有限公司 | 杀真菌组合物 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US12209099B2 (en) | 2019-03-15 | 2025-01-28 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| WO2024259085A2 (en) * | 2023-06-14 | 2024-12-19 | Alexion Pharmaceuticals, Inc. | Methods for the synthesis of complement factor d inhibitors and intermediates thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010034721A (ja) * | 2008-07-28 | 2010-02-12 | Fujitsu Ltd | パケットキャプチャ装置，パケットキャプチャ方法およびパケットキャプチャプログラム |
| KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Ｈｃｖ ｎｓ5ａ의 억제제 |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-09-24 JP JP2013530121A patent/JP5619289B2/ja not_active Expired - Fee Related
- 2010-09-24 BR BR112013008148A patent/BR112013008148A2/pt not_active IP Right Cessation
- 2010-09-24 MX MX2013002927A patent/MX2013002927A/es not_active Application Discontinuation
- 2010-09-24 CA CA2812699A patent/CA2812699A1/en not_active Abandoned
- 2010-09-24 EA EA201370078A patent/EA201370078A1/ru unknown
- 2010-09-24 WO PCT/US2010/050138 patent/WO2012039717A1/en not_active Ceased
- 2010-09-24 EP EP10761101.4A patent/EP2619195A1/en not_active Withdrawn
- 2010-09-24 CN CN2010800703399A patent/CN103249730A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537905A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| ME02321B (me) | Antivirusna jedinjenja | |
| JP2012512169A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2014515377A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2012528161A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2010535785A5 (enExample) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| JP2012504129A5 (enExample) | ||
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| JP2012504632A5 (enExample) | ||
| JP2015512860A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2011520906A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2013532725A5 (enExample) |